Foghorn Therapeutics (FHTX) Total Current Liabilities (2019 - 2026)

Foghorn Therapeutics' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $64.4 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 9.68% year-over-year to $64.4 million; the TTM figure through Mar 2026 stood at $64.4 million (down 9.68% YoY), while the FY2025 annual figure was $59.7 million, down 10.82% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $64.4 million, up from $59.7 million in the prior quarter.
• The five-year high for Total Current Liabilities was $85.1 million in Q3 2025, with the low at $48.0 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $56.6 million (2023), against an average of $59.7 million.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities jumped 195.39% in 2022, then dropped 10.82% in 2025.
• Foghorn Therapeutics' Total Current Liabilities stood at $55.2 million in 2022, then climbed by 5.85% to $58.4 million in 2023, then advanced by 14.64% to $67.0 million in 2024, then fell by 10.82% to $59.7 million in 2025, then gained by 7.81% to $64.4 million in 2026.
• Business Quant data shows FHTX's Total Current Liabilities at $64.4 million in Q1 2026, $59.7 million in Q4 2025, and $85.1 million in Q3 2025.